|Chemical and physical data|
|Molar mass||144.9 kg/mol g·mol−1|
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. As of May 2017[update], it is in Phase II clinical trials for the treatment of diabetic macular edema.
This drug is being developed by Regeneron Pharmaceuticals.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.
- Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
- Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems
|Bone ("-os-", "-s(o)-")|
|Angiogenesis inhibitor ("-anibi-")|
|Growth factor ("-gr(o)-")|
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|